240 related articles for article (PubMed ID: 18505919)
1. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.
Cole KA; Attiyeh EF; Mosse YP; Laquaglia MJ; Diskin SJ; Brodeur GM; Maris JM
Mol Cancer Res; 2008 May; 6(5):735-42. PubMed ID: 18505919
[TBL] [Abstract][Full Text] [Related]
2. The MYCN oncogene is a direct target of miR-34a.
Wei JS; Song YK; Durinck S; Chen QR; Cheuk AT; Tsang P; Zhang Q; Thiele CJ; Slack A; Shohet J; Khan J
Oncogene; 2008 Sep; 27(39):5204-13. PubMed ID: 18504438
[TBL] [Abstract][Full Text] [Related]
3. A rationalized definition of general tumor suppressor microRNAs excludes miR-34a.
Mockly S; Houbron É; Seitz H
Nucleic Acids Res; 2022 May; 50(8):4703-4712. PubMed ID: 35474387
[TBL] [Abstract][Full Text] [Related]
4. Double-stranded microRNA mimics can induce length- and passenger strand-dependent effects in a cell type-specific manner.
Goldgraben MA; Russell R; Rueda OM; Caldas C; Git A
RNA; 2016 Feb; 22(2):193-203. PubMed ID: 26670622
[TBL] [Abstract][Full Text] [Related]
5. Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.
Zarone MR; Misso G; Grimaldi A; Zappavigna S; Russo M; Amler E; Di Martino MT; Amodio N; Tagliaferri P; Tassone P; Caraglia M
Sci Rep; 2017 Dec; 7(1):17949. PubMed ID: 29263373
[TBL] [Abstract][Full Text] [Related]
6.
Kosti A; Du L; Shivram H; Qiao M; Burns S; Garcia JG; Pertsemlidis A; Iyer VR; Kokovay E; Penalva LOF
Mol Cancer Res; 2020 Jan; 18(1):68-78. PubMed ID: 31624087
[TBL] [Abstract][Full Text] [Related]
7. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells.
Rupaimoole R; Yoon B; Zhang WC; Adams BD; Slack FJ
iScience; 2020 Feb; 23(2):100878. PubMed ID: 32062455
[TBL] [Abstract][Full Text] [Related]
8. Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy.
Zhao Z; Wang W; Wang G; Huang Z; Zhou L; Lin L; Ou Y; Huang W; Zhang X; Wu C; Tao L; Wang Q
J Nanobiotechnology; 2023 Dec; 21(1):473. PubMed ID: 38066528
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential.
Fu J; Imani S; Wu MY; Wu RC
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835417
[TBL] [Abstract][Full Text] [Related]
10.
Bedekovics T; Hussain S; Zhang Y; Ali A; Jeon YJ; Galardy PJ
Cancer Res; 2021 Mar; 81(5):1321-1331. PubMed ID: 33355202
[TBL] [Abstract][Full Text] [Related]
11. Synthetic miR-34a against solid tumours: a predictable failure.
Mockly S; Seitz H
Br J Cancer; 2023 Feb; 128(3):478-480. PubMed ID: 36550206
[TBL] [Abstract][Full Text] [Related]
12. Non-Coding RNAs Participate in the Pathogenesis of Neuroblastoma.
Rezaei O; Honarmand Tamizkar K; Hajiesmaeili M; Taheri M; Ghafouri-Fard S
Front Oncol; 2021; 11():617362. PubMed ID: 33718173
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma.
Tivnan A; Tracey L; Buckley PG; Alcock LC; Davidoff AM; Stallings RL
BMC Cancer; 2011 Jan; 11():33. PubMed ID: 21266077
[TBL] [Abstract][Full Text] [Related]
14. Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor.
Jablonowski CM; Quarni W; Singh S; Tan H; Bostanthirige DH; Jin H; Fang J; Chang TC; Finkelstein D; Cho JH; Hu D; Pagala V; Sakurada SM; Pruett-Miller SM; Wang R; Murphy A; Freeman K; Peng J; Davidoff AM; Wu G; Yang J
Elife; 2024 Mar; 12():. PubMed ID: 38488852
[TBL] [Abstract][Full Text] [Related]
15. Role of non-coding RNAs as new therapeutic targets in regulating the EMT and apoptosis in metastatic gastric and colorectal cancers.
Ebrahimi N; Hakimzadeh A; Bozorgmand F; Speed S; Manavi MS; Khorram R; Farahani K; Rezaei-Tazangi F; Mansouri A; Hamblin MR; Aref AR
Cell Cycle; 2023 Oct; 22(20):2302-2323. PubMed ID: 38009668
[TBL] [Abstract][Full Text] [Related]
16. Role of non-coding RNAs in neuroblastoma.
Anoushirvani AA; Jafarian Yazdi A; Amirabadi S; Asouri SA; Shafabakhsh R; Sheida A; Hosseini Khabr MS; Jafari A; Tamehri Zadeh SS; Hamblin MR; Kalantari L; Talaei Zavareh SA; Mirzaei H
Cancer Gene Ther; 2023 Sep; 30(9):1190-1208. PubMed ID: 37217790
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation.
Van Goethem A; Deleu J; Yigit N; Everaert C; Moreno-Smith M; Vasudevan SA; Zeka F; Demuynck F; Barbieri E; Speleman F; Mestdagh P; Shohet J; Vandesompele J; Van Maerken T
NAR Cancer; 2023 Mar; 5(1):zcad002. PubMed ID: 36683916
[TBL] [Abstract][Full Text] [Related]
18. Remarkable Synergy When Combining EZH2 Inhibitors with YM155 Is H3K27me3-Independent.
Yang J; Davidoff AM
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612203
[TBL] [Abstract][Full Text] [Related]
19. Gene utility recapitulates chromosomal aberrancies in advanced stage neuroblastoma.
Ung CY; Levee TM; Zhang C; Correia C; Yeo KS; Li H; Zhu S
Comput Struct Biotechnol J; 2022; 20():3291-3303. PubMed ID: 35832612
[TBL] [Abstract][Full Text] [Related]
20. miR-15a and miR-15b modulate natural killer and CD8
Pathania AS; Prathipati P; Olwenyi OA; Chava S; Smith OV; Gupta SC; Chaturvedi NK; Byrareddy SN; Coulter DW; Challagundla KB
Mol Ther Oncolytics; 2022 Jun; 25():308-329. PubMed ID: 35663229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
